Hemoglobinopathies

Investigators of this multicenter trial that included 388 children and adults with sickle cell disease reported that poloxamer 188, an agent found to reduce blood viscosity and cell-cell interactions, did not significantly shorten the duration of vaso-occlusive episodes.